Search

Your search keyword '"Filippatos, Gerasimos"' showing total 43 results
Start Over Author "Filippatos, Gerasimos" Journal circulation
43 results on '"Filippatos, Gerasimos"'

2. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials

Author

Dimond, Matthew, Khan, Mohammad S, Fiuzat, Mona, Cleland, John G, Bhatt, Ankeet, Psotka, Mitchell, Anker, Stefan D, Butler, Javed, Felker, Michael, Mark, Daniel B, Carson, Peter E, Abraham, William T, Ahmad, Tariq, Lindenfeld, Joann, Vaduganathan, Muthiah, Whellan, David J, Vardeny, Orly, Solomon, Scott, Lewis, Eldrin F, Filippatos, Gerasimos, and OConnor, Christopher M

Published
2023
Full Text
View/download PDF

7. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Author

Butler, Javed, Filippatos, Gerasimos, Jamal Siddiqi, Tariq, Brueckmann, Martina, Böhm, Michael, Chopra, Vijay K., Pedro Ferreira, João, Januzzi, James L., Kaul, Sanjay, Piña, Ileana L., Ponikowski, Piotr, Shah, Sanjiv J., Senni, Michele, Vedin, Ola, Verma, Subodh, Peil, Barbara, Pocock, Stuart J., Zannad, Faiez, Packer, Milton, and Anker, Stefan D.

Published
2022
Full Text
View/download PDF

8. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Author

Pfeffer, Marc A., Claggett, Brian, Lewis, Eldrin F., Granger, Christopher B., Køber, Lars, Maggioni, Aldo P., Mann, Douglas L., McMurray, John J.V., Rouleau, Jean-Lucien, Solomon, Scott D., Steg, Philippe Gabriel, Berwanger, Otavio, Cikes, Maja, De Pasquale, Carmine G., Fernandez, Alberto, Filippatos, Gerasimos, Jering, Karola, Landmesser, Ulf, Menon, Venugopal, Merkely, Béla, Petrie, Mark C., Petrov, Ivo, Schou, Morten, Senni, Michele, Sim, David, van der Meer, Peter, Lefkowitz, Martin, Zhou, Yinong, Wang, Yi, and Braunwald, Eugene

Published
2022
Full Text
View/download PDF

9. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Author

Packer, Milton, Butler, Javed, Zannad, Faiez, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Schnaidt, Sven, Zeller, Cordula, Schnee, Janet M., and Anker, Stefan D.

Published
2021
Full Text
View/download PDF

11. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

Author

Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Marx, Nikolaus, Lam, Carolyn S.P., Schnaidt, Sven, Ofstad, Anne Pernille, Brueckmann, Martina, Jamal, Waheed, Bocchi, Edimar A., Ponikowski, Piotr, Perrone, Sergio V., Januzzi, James L., Verma, Subodh, Böhm, Michael, Ferreira, João Pedro, Pocock, Stuart J., Zannad, Faiez, and Packer, Milton

Published
2021
Full Text
View/download PDF

12. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Author

Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Schnaidt, Sven, and Zannad, Faiez

Published
2021
Full Text
View/download PDF

14. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

Author

Butler, Javed, primary, Filippatos, Gerasimos, additional, Siddiqi, Tariq Jamal, additional, Ferreira, João Pedro, additional, Brueckmann, Martina, additional, Bocchi, Edimar, additional, Böhm, Michael, additional, Chopra, Vijay K., additional, Giannetti, Nadia, additional, Iwata, Tomoko, additional, Januzzi, James L., additional, Kaul, Sanjay, additional, Piña, Ileana L., additional, Ponikowski, Piotr, additional, Rauch-Kröhnert, Ursula, additional, Shah, Sanjiv J., additional, Senni, Michele, additional, Sumin, Mikhail, additional, Verma, Subodh, additional, Zhang, Jian, additional, Pocock, Stuart J., additional, Zannad, Faiez, additional, Packer, Milton, additional, and Anker, Stefan D., additional

Published
2022
Full Text
View/download PDF

15. Decongestion with Acetazolamide in Acute Decompensated Heart Failure across the Spectrum of Left Ventricular Ejection Fraction: a Pre-specified Analysis from the ADVOR trial.

Author

Martens, Pieter, Dauw, Jeroen, Verbrugge, Frederik H., Nijst, Petra, Meekers, Evelyne, Augusto Jr, Silvio Nunes, Ter Maaten, Jozine M., Damman, Kevin, Mebazaa, Alexandre, Filippatos, Gerasimos, Ruschitzka, Frank, Tang, W.H. Wilson, Dupont, Matthias, Mullens, Wilfried, and Augusto, Silvio Nunes Jr

Published
2023
Full Text
View/download PDF

17. Abstract 12759: Iron Deficiency in Heart Failure is Associated With Upregulation of Pathways Also Related to Cancer Development

Author

Grote Beverborg, Niels, primary, van der Wal, Haye, additional, Lang, Chim C, additional, Dickstein, Kenneth, additional, Filippatos, Gerasimos, additional, Cleland, John, additional, Anker, Stefan D, additional, Metra, Marco, additional, van Veldhuisen, Dirk, additional, Voors, Adriaan A, additional, De Boer, Rudolf A, additional, and van der meer, peter, additional

Published
2021
Full Text
View/download PDF

18. Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction

Author

Boorsma, Eva M, primary, ter Maaten, Jozine M, additional, Damman, Kevin, additional, Pellicori, Pierpaolo, additional, Metra, Marco, additional, Dickstein, Kenneth, additional, van Veldhuisen, Dirk J, additional, Filippatos, Gerasimos, additional, Ng, Leong, additional, Anker, Stefan D, additional, Zannad, Faiez, additional, Cleland, John, additional, Voors, Adriaan A, additional, and Emmens, Lisa, additional

Published
2021
Full Text
View/download PDF

20. Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science.

Author

Agarwal, Anubha, Tromp, Jasper, Almahmeed, Wael, Angermann, Christiane, Chandramouli, Chanchal, Hyunjai Cho, Don-Ju Choi, Damasceno, Albertino, Filippatos, Gerasimos, Fonarow, Gregg C., Harikrishnan, Sivadasanpillai, Lund, Lars, Masoudi, Fred, Mensah, George A., Pathan, Asad, Perel, Pablo, Pinto, Fausto, Ribeiro, Antonio Luiz, Rich, Stuart, and Yasuhiko Sakata

Published
2024
Full Text
View/download PDF

21. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Author

Filippatos, Gerasimos, Anker, Stefan D., Agarwal, Rajiv MS, Ruilope, Luis M., Rossing, Peter, Bakris, George L., Tasto, Christoph, Joseph, Amer, Kolkhof, Peter, Lage, Andrea, Pitt, Bertram, Agarwal, Rajiv, and FIGARO-DKD Investigators

Subjects
*TYPE 2 diabetes, *HEART failure patients, *CHRONIC kidney failure, *DIABETIC nephropathies, *VENTRICULAR ejection fraction, *CHRONICALLY ill, *KIDNEY failure, *RESEARCH, *HETEROCYCLIC compounds, *RESEARCH methodology, *DISEASE incidence, *EVALUATION research, *COMPARATIVE studies, *RANDOMIZED controlled trials, *STATISTICAL sampling, *HEART failure, *DISEASE complications, CHRONIC kidney failure complications
Abstract

Background: Chronic kidney disease and type 2 diabetes are independently associated with heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) and FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease) trials, finerenone (a selective, nonsteroidal mineralocorticoid receptor antagonist) improved cardiovascular outcomes in patients with albuminuric chronic kidney disease and type 2 diabetes. These prespecified analyses from FIGARO-DKD assessed the effect of finerenone on clinically important HF outcomes.Methods: Patients with type 2 diabetes and albuminuric chronic kidney disease (urine albumin-to-creatinine ratio ≥30 to <300 mg/g and estimated glomerular filtration rate ≥25 to ≤90 mL per min per 1.73 m2, or urine albumin-to-creatinine ratio ≥300 to ≤5000 mg/g and estimated glomerular filtration rate ≥60 mL per min per 1.73 m2), without symptomatic HF with reduced ejection fraction, were randomized to finerenone or placebo. Time-to-first-event outcomes included new-onset HF (first hospitalization for HF [HHF] in patients without a history of HF at baseline); cardiovascular death or first HHF; HF-related death or first HHF; first HHF; cardiovascular death or total (first or recurrent) HHF; HF-related death or total HHF; and total HHF. Outcomes were evaluated in the overall population and in prespecified subgroups categorized by baseline HF history (as reported by the investigators).Results: Overall, 7352 patients were included in these analyses; 571 (7.8%) had a history of HF at baseline. New-onset HF was significantly reduced with finerenone versus placebo (1.9% versus 2.8%; hazard ratio [HR], 0.68 [95% CI, 0.50-0.93]; P=0.0162). In the overall population, the incidences of all HF outcomes analyzed were significantly lower with finerenone than placebo, including an 18% lower risk of cardiovascular death or first HHF (HR, 0.82 [95% CI, 0.70-0.95]; P=0.011), a 29% lower risk of first HHF (HR, 0.71 [95% CI, 0.56-0.90]; P=0.0043) and a 30% lower rate of total HHF (rate ratio, 0.70 [95% CI, 0.52-0.94]). The effects of finerenone on improving HF outcomes were not modified by a history of HF. The incidence of treatment-emergent adverse events was balanced between treatment groups.Conclusions: The results from these FIGARO-DKD analyses demonstrate that finerenone reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02545049. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.

Author

Filippatos, Gerasimos, Anker, Stefan D., Agarwal, Rajiv, Pitt, Bertram, Ruilope, Luis M., Rossing, Peter, Kolkhof, Peter, Schloemer, Patrick, Tornus, Ingo, Joseph, Amer, Bakris, George L., and FIDELIO-DKD Investigators

Subjects
*CHRONIC kidney failure, *TYPE 2 diabetes, *CHRONICALLY ill, *DIABETIC nephropathies, *HEART failure patients, *CARDIOVASCULAR disease prevention, *RESEARCH, *HETEROCYCLIC compounds, *RESEARCH methodology, *MEDICAL cooperation, *EVALUATION research, *COMPARATIVE studies, *BLIND experiment
Abstract

Background: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with optimized renin-angiotensin system blockade. Compared with placebo, finerenone reduced the composite kidney and cardiovascular outcomes. We report the effect of finerenone on individual cardiovascular outcomes and in patients with and without history of atherosclerotic cardiovascular disease (CVD).Methods: This randomized, double-blind, placebo-controlled trial included patients with type 2 diabetes and urine albumin-to-creatinine ratio 30 to 5000 mg/g and an estimated glomerular filtration rate ≥25 to <75 mL per min per 1.73 m2, treated with optimized renin-angiotensin system blockade. Patients with a history of heart failure with reduced ejection fraction were excluded. Patients were randomized 1:1 to receive finerenone or placebo. The composite cardiovascular outcome included time to cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. Prespecified cardiovascular analyses included analyses of the components of this composite and outcomes according to CVD history at baseline.Results: Between September 2015 and June 2018, 13 911 patients were screened and 5674 were randomized; 45.9% of patients had CVD at baseline. Over a median follow-up of 2.6 years (interquartile range, 2.0-3.4 years), finerenone reduced the risk of the composite cardiovascular outcome compared with placebo (hazard ratio, 0.86 [95% CI, 0.75-0.99]; P=0.034), with no significant interaction between patients with and without CVD (hazard ratio, 0.85 [95% CI, 0.71-1.01] in patients with a history of CVD; hazard ratio, 0.86 [95% CI, 0.68-1.08] in patients without a history of CVD; P value for interaction, 0.85). The incidence of treatment-emergent adverse events was similar between treatment arms, with a low incidence of hyperkalemia-related permanent treatment discontinuation (2.3% with finerenone versus 0.8% with placebo in patients with CVD and 2.2% with finerenone versus 1.0% with placebo in patients without CVD).Conclusions: Among patients with chronic kidney disease and type 2 diabetes, finerenone reduced incidence of the composite cardiovascular outcome, with no evidence of differences in treatment effect based on preexisting CVD status. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02540993. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

23. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Author

Yancy, Clyde W., primary, Jessup, Mariell, additional, Bozkurt, Biykem, additional, Butler, Javed, additional, Casey, Donald E., additional, Colvin, Monica M., additional, Drazner, Mark H., additional, Filippatos, Gerasimos S., additional, Fonarow, Gregg C., additional, Givertz, Michael M., additional, Hollenberg, Steven M., additional, Lindenfeld, JoAnn, additional, Masoudi, Frederick A., additional, McBride, Patrick E., additional, Peterson, Pamela N., additional, Stevenson, Lynne Warner, additional, and Westlake, Cheryl, additional

Published
2017
Full Text
View/download PDF

24. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment

Author

Antman, Elliott M., primary, Bax, Jeroen, additional, Chazal, Richard A., additional, Creager, Mark A., additional, Filippatos, Gerasimos, additional, Halperin, Jonathan L., additional, Houser, Steven, additional, Lindenfeld, JoAnn, additional, Pinto, Fausto J., additional, Vardas, Panos, additional, Walsh, Mary Norine, additional, Williams, Kim A., additional, and Zamorano, Jose L., additional

Published
2016
Full Text
View/download PDF

25. Abstract 17212: 30-day All-cause Readmission is Associated With a Significantly Higher Subsequent All-cause Mortality and Costly Readmissions Among Older Medicare Beneficiaries Hospitalized for Heart Failure

Author

Arundel, Cherinne, primary, Khosla, Rahul, additional, Faselis, Charles, additional, Morgan, Charity J, additional, Zhang, Sijian, additional, Blackman, Marc, additional, Fletcher, Ross D, additional, Wu, Wen-Chih, additional, Butler, Javed, additional, Fonarow, Gregg C, additional, Deedwania, Prakash, additional, White, Michel, additional, Aronow, Wilbert S, additional, Filippatos, Gerasimos S, additional, Anker, Stefan D, additional, Ahmed, Ali, additional, and Allman, Richard M, additional

Published
2015
Full Text
View/download PDF

26. Abstract 18709: Older Former Smokers with <32 Pack-Years of Prior Smoking and <15 Years of Abstinence Have Lower Risk of Incident Heart Failure and Cardiovascular Mortality But Not of All-Cause Mortality: Findings From a Prospective Population Study

Author

Ahmed, Amiya A, primary, Morgan, Charity J, additional, Fonarow, Gregg C, additional, Prabhu, Sumanth, additional, Bittner, Vera, additional, Patel, Kanan, additional, Deedwania, Prakash, additional, Filippatos, Gerasimos, additional, Anker, Stefan D, additional, Allman, Richard M, additional, Aronow, Wilbert, additional, and Ahmed, Ali, additional

Published
2013
Full Text
View/download PDF

27. Abstract 18879: Low Income is Associated With Higher Risk of Cardiovascular Events and Mortality in Community Dwelling, Medicare Eligible, College Educated Older Adults With Background Professional Occupation

Author

Ahmed, Amiya A, primary, Morgan, Charity J, additional, Fonarow, Gregg C, additional, Patel, Kanan, additional, Bittner, Vera, additional, Deedwania, Prakash, additional, Aronow, Wilbert, additional, Filippatos, Gerasimos, additional, Anker, Stefan, additional, Prabhu, Sumanth, additional, Allman, Richard M, additional, and Ahmed, Ali, additional

Published
2013
Full Text
View/download PDF

28. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Author

WRITING COMMITTEE MEMBERS, Yancy, Clyde W, Jessup, Mariell, Bozkurt, Biykem, Butler, Javed, Casey, Donald E Jr, Colvin, Monica M, Drazner, Mark H, Filippatos, Gerasimos, Fonarow, Gregg C, Givertz, Michael M, Hollenberg, Steven M, Lindenfeld, JoAnn, Masoudi, Frederick A, McBride, Patrick E, Peterson, Pamela N, Stevenson, Lynne Warner, and Westlake, Cheryl

Published
2016
Full Text
View/download PDF

35. Acute Heart Failure Syndromes

Author

Gheorghiade, Mihai, primary, Zannad, Faiez, additional, Sopko, George, additional, Klein, Liviu, additional, Piña, Ileana L., additional, Konstam, Marvin A., additional, Massie, Barry M., additional, Roland, Edmond, additional, Targum, Shari, additional, Collins, Sean P., additional, Filippatos, Gerasimos, additional, and Tavazzi, Luigi, additional

Published
2005
Full Text
View/download PDF

40. Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.

Author

Stone GW, Lindenfeld J, Rodés-Cabau J, Anker SD, Zile MR, Kar S, Holcomb R, Pfeiffer MP, Bayes-Genis A, Bax JJ, Bank AJ, Costanzo MR, Verheye S, Roguin A, Filippatos G, Núñez J, Lee EC, Laufer-Perl M, Moravsky G, Litwin SE, Prihadi E, Gada H, Chung ES, Price MJ, Thohan V, Schewel D, Kumar S, Kische S, Shah KS, Donovan DJ, Zhang Y, Eigler NL, and Abraham WT

Abstract

Background: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis., Methods: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiovascular or neurological events at 30 days compared with a prespecified performance goal of 11%. The primary effectiveness outcome was the hierarchical composite ranking of all-cause death, cardiac transplantation or left ventricular assist device implantation, HF hospitalization, outpatient worsening HF events, and change in quality of life from baseline measured by the Kansas City Cardiomyopathy Questionnaire overall summary score through maximum 2-year follow-up, assessed when the last enrolled patient reached 1-year follow-up, expressed as the win ratio. Prespecified hypothesis-generating analyses were performed on patients with reduced and preserved LVEF., Results: Between October 24, 2018, and October 19, 2022, 508 patients were randomized at 94 sites in 11 countries to interatrial shunt treatment (n=250) or a placebo procedure (n=258). Median (25th and 75th percentiles) age was 73.0 years (66.0, 79.0), and 189 patients (37.2%) were women. Median LVEF was reduced (≤40%) in 206 patients (40.6%) and preserved (>40%) in 302 patients (59.4%). No primary safety events occurred after shunt implantation (upper 97.5% confidence limit, 1.5%; P <0.0001). There was no difference in the 2-year primary effectiveness outcome between the shunt and placebo procedure groups (win ratio, 0.86 [95% CI, 0.61-1.22]; P =0.20). However, patients with reduced LVEF had fewer adverse cardiovascular events with shunt treatment versus placebo (annualized rate 49.0% versus 88.6%; relative risk, 0.55 [95% CI, 0.42-0.73]; P <0.0001), whereas patients with preserved LVEF had more cardiovascular events with shunt treatment (annualized rate 60.2% versus 35.9%; relative risk, 1.68 [95% CI, 1.29-2.19]; P =0.0001; P interaction <0.0001). There were no between-group differences in change in Kansas City Cardiomyopathy Questionnaire overall summary score during follow-up in all patients or in those with reduced or preserved LVEF., Conclusions: Transcatheter interatrial shunt implantation was safe but did not improve outcomes in patients with HF. However, the results from a prespecified exploratory analysis in stratified randomized groups suggest that shunt implantation is beneficial in patients with reduced LVEF and harmful in patients with preserved LVEF., Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03499236.

Published
2024
Full Text
View/download PDF

41. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Author

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, and Westlake C

Subjects
Female, Heart Failure physiopathology, Humans, Male, Practice Guidelines as Topic, United States, Advisory Committees, American Heart Association, Heart Failure diagnosis, Heart Failure therapy
Published
2016
Full Text
View/download PDF

42. Third universal definition of myocardial infarction.

Author

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, and Mendis S

Subjects
Humans, Myocardial Infarction physiopathology, Myocardial Ischemia physiopathology, Cardiology standards, Diagnostic Techniques, Cardiovascular standards, Myocardial Infarction diagnosis, Myocardial Ischemia diagnosis
Published
2012
Full Text
View/download PDF

43. Universal definition of myocardial infarction.

Author

Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, and Al-Attar N

Subjects
Cause of Death, Humans, International Cooperation, Myocardial Infarction pathology, Myocardial Ischemia, Public Policy, Myocardial Infarction classification, Myocardial Infarction diagnosis, Terminology as Topic
Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results